Methadone Maintenance Therapy Decreases the Rate of Antiretroviral Therapy Discontinuation Among HIV-Positive Illicit Drug Users
- 348 Downloads
We sought to examine whether methadone maintenance therapy (MMT) decreased rates of antiretroviral therapy (ART) discontinuation and was associated with plasma HIV RNA responses among a cohort of illicit drug users. Cumulative ART discontinuation rates were estimated using Kaplan–Meier methods and factors independently associated with ART discontinuation were identified using Cox proportional hazards regression. Engagement in MMT was negatively and independently associated with ART discontinuation [Adjusted Relative Hazard = 0.67 (95 % CI 0.54–0.83); p < 0.001]. Among participants receiving ART and MMT, 81.6 % of plasma HIV-1 RNA assessments were <500 copies/mL, while 65.81 % of HIV-1 RNA assessments among those prescribed ART without MMT were <500 copies/mL (p < 0.001). These results demonstrate that engagement in MMT conferred a protective benefit against ART discontinuation and was associated with a significant increase in plasma HIV RNA suppression among HIV-infected opioid-dependent drug users.
KeywordsHIV Drug use Antiretroviral therapy Methadone Discontinuation
The authors thank the study participants for their contribution to the research, as well as current and past researchers and staff. We would specifically like to thank Deborah Graham, Tricia Collingham, Caitlin Johnston, and Steve Kain for their research and administrative assistance. The study was supported by the US National Institutes of Health (R01DA021525) and the Canadian Institutes of Health Research (MOP-79297, RAA-79918). Thomas Kerr and M.-J. Milloy are supported by the Michael Smith Foundation for Health Research. M.-J. Milloy is also supported by the Canadian Institutes of Health Research. This research was undertaken, in part, thanks to funding from the Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine which supports Dr. Evan Wood.
- 1.Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investig N Engl J Med. 1998;338(13):853.Google Scholar
- 11.Aceijas C, Oppenheimer E, Stimson GV, Ashcroft RE, Matic S, Hickman M. Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the “Treating 3 million by 2005. making it happen The WHO strategy” (“3 by 5”). Addiction. 2006;101(9):1246–53.PubMedCrossRefGoogle Scholar
- 17.Wood E, Montaner JS, Braitstein P, Yip B, Schechter MT, O’Shaughnessy MV, et al. Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health. Int J Drug Pol. 2003;15(2):133–38.Google Scholar
- 22.Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy(HAART) adherence: evidence from the MANIF 2000 cohort study. Addiction. 2008;103(11):1828–36.PubMedCrossRefGoogle Scholar
- 25.Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JSG. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4(+) cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003;139(10):810–6.PubMedCrossRefGoogle Scholar
- 43.Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009(2):CD002209.Google Scholar